Cover Image
市場調查報告書

認知功能障礙:開發中產品分析

Cognitive Impairment - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 199740
出版日期 內容資訊 英文 288 Pages
訂單完成後即時交付
價格
Back to Top
認知功能障礙:開發中產品分析 Cognitive Impairment - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 288 Pages
簡介

認知障礙也被稱之為認知症,特徵是在記憶、新事物的學習、集中或是影響每天生活的決定上都會有所障礙的狀態。主要的症狀包含有記憶障礙、視覺問題、情緒低落、易怒狀態和攻擊性、不安,及漠不關心等。致病的危險因子有年齡、性別、家族病史,還有種種與腦血管疾病息息相關的其他主要風險因素(高血壓、高膽固醇症、糖尿病及抽煙),都有可能成為認知障礙變性形態的原因。

本報告提供全球各國治療認知障礙所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

認知功能障礙概要

治療藥的開發

  • 認知功能障礙開發中產品:概要
  • 認知功能障礙開發中產品:比較分析

各企業開發中的認知功能障礙治療藥

大學/研究機關研究中的認知功能障礙治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

認知功能障礙治療藥:開發中的產品一覽(各企業)

認知功能障礙治療藥:研究中的產品一覽(各大學/研究機關)

認知功能障礙開發治療藥的企業

認知功能障礙:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介(產品概要,功能機制,研究開發(R&D)的發展情形)

認知功能障礙治療藥:開發中產品的最新趨勢

認知功能障礙治療藥:暫停開發的產品

認知功能障礙治療藥:中止開發的產品

認知功能障礙相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8469IDB

Summary

Global Markets Direct's, 'Cognitive Impairment - Pipeline Review, H2 2016', provides an overview of the Cognitive Impairment pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
  • The report reviews pipeline therapeutics for Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cognitive Impairment therapeutics and enlists all their major and minor projects
  • The report assesses Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cognitive Impairment

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Cognitive Impairment Overview
  • Therapeutics Development
  • Cognitive Impairment - Therapeutics under Development by Companies
  • Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
  • Cognitive Impairment - Pipeline Products Glance
  • Cognitive Impairment - Products under Development by Companies
  • Cognitive Impairment - Products under Investigation by Universities/Institutes
  • Cognitive Impairment - Companies Involved in Therapeutics Development
  • Cognitive Impairment - Therapeutics Assessment
  • Drug Profiles
  • Cognitive Impairment - Dormant Projects
  • Cognitive Impairment - Discontinued Products
  • Cognitive Impairment - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cognitive Impairment, H2 2016
  • Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cognitive Impairment - Pipeline by AbbVie Inc, H2 2016
  • Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Cognitive Impairment - Pipeline by AgeneBio Inc., H2 2016
  • Cognitive Impairment - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Astellas Pharma Inc., H2 2016
  • Cognitive Impairment - Pipeline by AstraZeneca Plc, H2 2016
  • Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Cognitive Impairment - Pipeline by Cardax, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Cerecor Inc., H2 2016
  • Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2016
  • Cognitive Impairment - Pipeline by Cognition Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
  • Cognitive Impairment - Pipeline by Coronis Partners Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2016
  • Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H2 2016
  • Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Genzyme Corporation, H2 2016
  • Cognitive Impairment - Pipeline by H. Lundbeck A/S, H2 2016
  • Cognitive Impairment - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Cognitive Impairment - Pipeline by IntelGenx Corp., H2 2016
  • Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Iproteos S.L., H2 2016
  • Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Luc Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Merck & Co., Inc., H2 2016
  • Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Neuralstem, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2016
  • Cognitive Impairment - Pipeline by NLS Pharma Group, H2 2016
  • Cognitive Impairment - Pipeline by Octapharma AG, H2 2016
  • Cognitive Impairment - Pipeline by Omeros Corporation, H2 2016
  • Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016
  • Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Pfizer Inc., H2 2016
  • Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Saniona AB, H2 2016
  • Cognitive Impairment - Pipeline by SeneXta Therapeutics SA, H2 2016
  • Cognitive Impairment - Pipeline by Shire Plc, H2 2016
  • Cognitive Impairment - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Spherium Biomed S.L., H2 2016
  • Cognitive Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Cognitive Impairment - Pipeline by Tetra Discovery Partners LLC, H2 2016
  • Cognitive Impairment - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Vicore Pharma AB, H2 2016
  • Cognitive Impairment - Pipeline by Virogenomics BioDevelopment, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cognitive Impairment - Dormant Projects, H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..1), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..2), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..3), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..4), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..5), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..6), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..7), H2 2016
  • Cognitive Impairment - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cognitive Impairment, H2 2016
  • Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top